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cost-effectiveness analysis. Initial responses suggest that manufacturers will accept the 
challenge to improve the quality of available evidence to support future decisions.
CASE3
THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP:  
INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR 
ROBOTIC PROSTATECTOMY
Adams E
Veterans Health Administration, Boston, MA, USA
ORGANIZATION: Veterans Health Administration (VHA) Ofﬁce of Patient Care 
Services provides policy and program development and oversight of clinical care 
delivered to 7.8m veterans nationally. PROBLEM OR ISSUE ADDRESSED: Should 
VHA adopt robotic prostatectomy (RP) for use in clinical care? If so, how should it 
be implemented? GOALS: (1) Apply a new health technology assessment (HTA) 
process for evaluating FDA-approved non-IT and non-pharmacologic new and emerg-
ing health care technologies that draws upon a wide range of VHA expertise as well 
as clinical research. (2) Make policy recommendations on the need, purchase, and 
implementation of these technologies in VHA clinical care in a timely fashion. OUT-
COMES ITEMS USED IN THE DECISION: Available clinical efﬁcacy/effectiveness, 
cost-effectiveness and safety data from the literature, regulatory status, utilization and 
cost analysis (UCA). IMPLEMENTATION STRATEGY: The Technology Assessment 
Advisory Group (TAAG) applied input from HTA, a clinical expert panel and a utiliza-
tion and cost analysis to make evidence-based recommendations on the acquisition, 
use and funding of RP in VA. RESULTS: As of 2006 evidence from heterogeneous 
case series demonstrated the safety and feasibility of RP. Its clinical use was limited 
by: high initial investment and operating costs; substantial training requirements; and 
lack of multicenter experience and clinical trial data from which to determine effective-
ness and cost-effectiveness relative to current practices. The impact of RP on the design 
and work processes in the surgical theater was also unclear. Fulﬁlling research and 
education missions and enhancing prestige and proﬁt were the primary motivators to 
its technological diffusion. UCA showed that patient recapture estimates of $13,000/
year would not offset the costs unique to the robotic system, and therefore, would 
not be economically viable. There are insufﬁcient research data and cost beneﬁt to 
justify widespread purchase and implementation of this technology solely for RP. 
Cautious diffusion to centers of excellence with skills and infrastructure to support 
the technology was recommended, as were options to help defray costs such as leasing 
the robotic system, providing training to outsiders and/or providing this option to the 
Dept of Defense. LESSONS LEARNED: The TAAG process proved feasible and effec-
tive in supporting informed and timely policy recommendations for the purchase and 
use of RP in a manner that enhances quality of care in a environment of cost-contain-
ment. After a one-year moratorium, VHA guidance was created to help individual 
facilities make an informed make or buy decision based on demonstration of an 
appropriate infrastructure in place to support training, backup, maintenance, and 
outcome data collection. The guidance included site visit and approval from the VHA 
National Surgery Program with oversight of outcome data collection, which continues 
today.
CASE4
NEW FINDINGS FROM INTEGRATING ADMINISTRATIVE AND 
FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H1, Levit K2, Sun YC3
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters, 
Washington, DC, USA, 3Thomson Reuters, Santa Barbara, CA, USA
ORGANIZATION: Agency for Healthcare Research and Quality (funding organiza-
tion), Thomson Reuters PROBLEM OR ISSUE ADDRESSED: Hospital administrative 
data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-illness” 
studies because they contain large numbers of cases for speciﬁc conditions and pro-
cedures and because charge information is available. While these data generally 
contain information on how much the facility charged for the hospital stay, they lack 
information on the cost to provide care and the amount reimbursed for care. In the 
past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost 
of providing care. AHRQ is piloting a project to create price-to-charge ratios that will 
be used in conjunction with charge information collected on hospital discharge records 
to estimate the “price” of inpatient hospital care. The term “price” reﬂects the amount 
that hospitals are paid by insurers and consumers based on payer revenue information 
for each hospital. This is the amount of revenue that hospitals actually receive, net of 
any discounts negotiated with insurers. These ratios have been linked to the Healthcare 
Cost and Utilization Project (HCUP) State Inpatient Databases (SID) for 5 states. The 
HCUP SID ﬁles contain the universe of inpatient discharge abstracts (including infor-
mation on charges) in participating States, translated into a uniform format to facili-
tate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, 
encompassing about 90 percent of all U.S. community hospital discharges. The 
impetus for this project is to make health care information more transparent to con-
sumers. While the addition of price information will help consumers make more 
informed choices about hospitalizations for themselves and their families, this infor-
mation will also be valuable for researchers by providing alternatives to measuring 
resource use that are better suited for their studies. This presentation builds on last 
year’s talk by presenting price results for 5 states. GOALS: The short-term goals of 
this project include: · Estimate prices by payer (Medicare, Medicaid, Private, and 
Self-pay) for common diagnoses in 5 states for 2006 · Assess the credibility of esti-
mated prices (“proof-of-concept”) · Evaluate price differences for major payers, geo-
graphic areas, and common diagnoses. The long term goals of this project include: · 
Extend study to a total of 10 states · Create models to estimate prices for HCUP states 
not included in the pilot · Provide states with information on hospital average prices 
that can be used to populate a Website where consumers can explore pricing for 
common diagnoses · Release prices publicly on AHRQ databases to explore inpatient 
pricing by market area to address research issues such as competition among hospitals, 
pricing differentials between payers, relationship between prices and quality, and 
effects of hospital entry on prices. OUTCOMES ITEMS USED IN THE DECISION: 
HCUP data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-
illness” studies because they contain large numbers of cases for speciﬁc conditions and 
procedures and because charge and estimated cost information is available. The addi-
tion of estimated prices will provide researchers an additional tool to more effectively 
conduct their studies. IMPLEMENTATION STRATEGY: AHRQ solicited participa-
tion of HCUP Partner organizations that have access to hospital revenue information 
by payer and are willing to release state-level charge and price information broken 
out by the four broad payer groups and broad diagnostic categories. Initially, AHRQ 
is utilizing information from 5 HCUP SID Partner States in conjunction with hospital-
speciﬁc revenue information to develop prices for hospitalizations. RESULTS: Prices 
have been estimated for 5 states. We show the consistency and reasonableness of 
estimated prices by presenting the average prices of speciﬁc diagnosis by payers, states, 
and metropolitan areas. In addition, average prices by bed-size, teaching status, and 
hospital ownership are examined. One important advantage of using “prices” rather 
than “costs” or “charges” is that prices are speciﬁc to each payer group, reﬂecting the 
sum of contractual and other adjustments. We demonstrate the differences in resource 
use as measured by “charges,” “costs,” and “prices.” An explanation of what these 
concepts will be discussed. LESSONS LEARNED: To date, the lessons learned include: 
1. The number of States that collect ﬁnancial information by major payers for each 
hospital is limited. 10 States have been identiﬁed with most of the detailed information 
required. 2. While States may collect gross and net revenue information by payer, not 
all separate these revenues completely for inpatient and outpatient services and for 
the major payer groups. Estimating methods have been developed to address these 
issues. 3. Deﬁnitions of revenues and the level of detailed data collection vary consider-
ably among States and needs to be reconciled.
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CM1
ADHERENCE, DISCONTINUATION, AND SWITCHING OF BIOLOGIC 
THERAPIES IN MEDICAID ENROLLEES WITH RHEUMATOID ARTHRITIS
Li P, Blum MA, Feldt JMV, Hennessy S, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: Biological therapies are an expensive but important advance in the 
management of RA. The potential therapeutic beneﬁts of biologics demonstrated in 
clinical trials may be undermined by poor adherence and early discontinuation of 
treatment (i.e., non-persistence) in clinical practice. This study examined adherence, 
discontinuation, and switching of Rheumatoid Arthritis (RA) biologics over a one year 
period following initiation of the biologic treatment in Medicaid patients with RA. 
METHODS: The study sample consisted of Medicaid patients with RA in California, 
Florida and New York who had newly initiated etanercept (n = 1359), anakinra (n = 
267), or inﬂiximab (n = 1012) between January 1, 2000 and December 31, 2002. 
Adherence (proportion of days covered (PDC) ≥ 0.80), discontinuation (90-day con-
tinuous gap), and switching (initiation of second biologic within 90 days of discontinu-
ation date of index biologic) were measured during the 12-months post-index biologic 
initiation. Sensitivity analyses were conducted by varying the thresholds to deﬁne these 
measures. Logistic regressions examined the factors associated with RA biologic 
adherence and discontinuation. RESULTS: Anakinra users had the lowest mean PDC 
(0.36) and percent adherent patients (10.5%) followed by etanercept users (mean 
PDC:0.57; % adherent:32%) and inﬂiximab users (mean PDC:0.64; % adher-
ent:43%). All three groups had high discontinuation rates (41% etanercept, 76% 
anakinra, and 41% inﬂiximab). Few patients who discontinued the index biologic 
switched to another biologic (0.2% to 9%). Logistic regressions found that patients 
in Florida had lower odds of being adherent and higher odds of discontinuing their 
index biologic than patients in California. Consistent with descriptive results, 
Anakinra users had lower odds and inﬂiximab users had higher odds of being adherent 
than etanercept users. Anakinra users had higher odds of discontinuation than etan-
ercept users. CONCLUSIONS: This study highlights poor adherence and premature 
discontinuation without concurrent switching of RA biologics that should raise 
concern for clinicians as well as payers.
CM2
EFFECTS OF NONADHERENCE WITH ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS ON 
HOSPITALIZATION AND MORTALITY AMONG PATIENTS WITH 
DIABETES
Yang Y1, Banahan BF1, Pace PF2
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA
OBJECTIVES: The objective was to determine the effect of nonadherence to angio-
tensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and 
subsequent diabetes-related hospitalization and mortality among patients with diabe-
tes enrolled in a state Medicaid program. METHODS: This is a retrospective cohort 
study of patients with diabetes using Medicaid pharmacy and medical claims data. 
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Diabetic patients with continuous coverage from January 2002 to December 2004 in 
a state Medicaid program, and who had an index prescription claim for ACEI/ARB 
in the ﬁrst six months of 2002 were included in the study. Adherence with ACEI/ARB 
therapy was measured using the proportion of days covered (PDC) during the 
12-month post-index period. Nonadherence was deﬁned as PDC < 0.8. The primary 
outcomes of interest were diabetes-related hospitalization and all-cause mortality in 
the follow-up period (end of post-index period to December 31, 2004). Multivariate 
regression analyses were performed to assess the independent effect of nonadherence 
with ACEI/ARB on outcome measures. RESULTS: 14,428 patients met our inclusion 
criteria. Among them, 75% were females and the mean age was 60.5 (±14.2) years. 
About 69% were nonadherent with prescribed ACEI/ARB therapy. During follow-up, 
10.9% patients had diabetes-related hospitalizations and 1.1% died for any reason. 
After controlling for baseline patient characteristics including age, gender, race, prior 
hospitalization, and comorbidities (Charlson comorbidity index), in comparison to 
adherent patients, the odds for diabetes-related hospital admission was 72.7% (OR: 
1.727; 95%CI: 1.508–1.976) higher for nonadherent patients. The odds for all-cause 
mortality were not statistically signiﬁcant between adherent and nonadherent patients 
(OR: 1.011; 95%CI: 0.721–1.419). Results of sensitivity analyses stratifying on 
patient age were consistent with our primary ﬁndings. CONCLUSIONS: The results 
suggest that nonadherence to ACEI/ARB is common among diabetic patients enrolled 
in a state Medicaid program. Nonadherence to ACEI/ARB appears to be associated 
with higher risks for diabetes-related hospitalization.
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IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON HEALTH CARE 
UTILIZATION IN PATIENTS WITH COMORBID TYPE II DIABETES AND 
CARDIOVASCULAR DISEASE
Nichol MB1, An JJ1, Wu J1, Priest J2, Knight TK1, Cantrell C2
1University of Southern California, Los Angeles, CA, USA, 2GlaxoSmithKline, RTP, NC, USA
OBJECTIVES: To investigate the association of multiple medication compliance with 
health care utilization. METHODS: We identiﬁed patients ≥40 years of age with a 
diagnosis of type II diabetes and comorbid cardiovascular disease (CVD) including 
hypertension, coronary artery disease, and heart failure from California Medicaid 
claim data between 2002 and 2004. Proportion of days covered ≥0.8 was used to 
assess medication compliance. Multivariate two-part models were used to determine 
health care utilization in 2004 across different medication compliance statuses after 
controlling for confounding factors. RESULTS: A total of 21,740 patients were 
analyzed. Only 18% of patients were compliant with both diabetes and CVD medica-
tions, 32% compliant with only diabetes medication, and 7% with only CVD medica-
tion. Adherence to both diabetes and CVD medications was signiﬁcantly associated 
with decreased number of emergency room (ER) visits (0.052 ± 0.011, p < 0.0001), 
decreased hospitalization (0.025 ± 0.004, p < 0.0001), increased number of outpatient 
visits (10.02 ± 0.67, p < 0.001) and increased number of prescription ﬁlls (35 ± 0.89, 
p < 0.0001). Mean covariate adjusted ER visits (0.26 ± 0.62) in patients who did not 
ﬁll appropriate medications or were noncompliant with medications were signiﬁcantly 
higher than those compliant with both diabetes and CVD medications (0.19 ± 0.42, 
p = 0.000), or those compliant with only diabetes medications (0.21 ± 0.46, p = 0.000). 
Mean adjusted number of hospitalizations in patients compliant with only CVD 
medication (0.11 ± 0.31, p = 0.01) was signiﬁcantly higher than those compliant with 
both diabetes and CVD medications (0.08 ± 0.22, p = 0.01) or compliant with only 
diabetes medication (0.08 ± 0.20, p = 0.001). CONCLUSIONS: Compliance with 
multiple medications was signiﬁcantly associated with a decrease in the number of ER 
visits and hospitalizations in a California Medicaid population with type II diabetes 
and comorbid CVD.
PODIUM SESSION III: CARDIOVASCULAR OUTCOMES  
RESEARCH STUDIES
CV1
PERIOPERATIVE BLOOD PRESSURE CONTROL DURING CARDIAC 
SURGERY REDUCES HOSPITALIZATION COSTS
Ishak K1, Stolar M2, Wang Y3, Alvarez P2, Hu MY3, Williams GC3, Ferguson J3, Aronson 
S4, Multz AS5, Dyke CM6, Getsios D7
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, 
Lexington, MA, USA, 3The Medicines Company, Parsippany, NJ, USA, 4Duke University 
School of Medicine, Durham, NC, USA, 5Albert Einstein College of Medicine, New Hyde 
Park, NY, USA, 6Brazosport Regional Health System, Lake Jackson, TX, USA, 7United 
BioSource Corporation, Halifax, NS, Canada
OBJECTIVES: The association between perioperative blood pressure (BP) control and 
reduced risks of death and complications in cardiac surgery patients has been demon-
strated in the ECLIPSE (Evaluation of CLevidipine In the Perioperative Treatment of 
Hypertension Assessing Safety Events) trials. This study evaluated the relationship 
between perioperative BP control and the total costs of hospitalization and 30-day 
readmission in ECLIPSE patients undergoing coronary artery bypass grafting (CABG) 
or valve surgery. METHODS: Cost data were obtained from the Massachusetts Acute 
Hospital Case Mix Database for 2005–2007 for patients undergoing cardiac surgery 
and analyzed separately for patients who experienced death, myocardial infarction, 
stroke, bleeding, infections, renal failure, multiple complications, or none of these 
complications. These data were used to assign 2009 hospitalization costs to ECLIPSE 
patients by matching their complications and length of stay. BP control was deﬁned 
as area under the curve (AUC) capturing the magnitude and duration of systolic blood 
pressure excursions outside pre-speciﬁed ranges and expressed in units of mm Hg × 
minutes/hour. Smaller AUC values represent more precise BP control. The relationship 
between AUC and costs was examined using a log-normal model. Outcomes were 
evaluated for all patients, patients undergoing CABG, patients undergoing valve 
surgery, and patients with both procedures. RESULTS: Mean costs for patients in 
ECLIPSE were $52,941 and ranged from $47,349 for patients with CABG only to 
$79,442 for patients with CABG and valve surgery. After controlling for potential 
confounders, perioperative AUC below 10 was associated with 5.9% lower costs 
(95% conﬁdence interval of 0.9%-11.2%) with the largest reduction in patients 
undergoing CABG surgery only (7.8%). For the population with AUC above 10, 
reducing AUC to below 10 was predicted to reduce costs by $3080, ranging from 
$891-$4444 depending on the surgery group. CONCLUSIONS: Effective periopera-
tive BP control in patients undergoing cardiac surgery has a signiﬁcant impact on 
hospitalization costs.
CV2
USING AN INTERRUPTED TIME SERIES ANALYSIS TO ASSESS THE 
IMPACT OF VALSARTAN INITIATION ON MEDICAL COSTS FOR 
PATIENTS WITH HYPERTENSION
Sun P1, Chang JR2, Zhang J2, Kahler KH2
1Kailo Research Group, Indianapolis, IN, USA, 2Novartis Pharmaceuticals Corporation 
Medical, East Hanover, NJ, USA
OBJECTIVES: This study examines whether valsartan initiation is associated with a 
post-initiation reduction in medical costs among hypertensive patients. METHODS: 
A retrospective interrupted time series design was used with a large, US national 
claims database for the period of 2004–2008. Hypertensive patients who initiated 
valsartan between the ages of 20 and 63, and had continuous enrollment for 
24-month pre- and 24-months post- valsartan initiation were selected. Patients’ 
monthly medical costs were calculated based on individual claims. To detect a post-
initiation reduction in the medical costs, interrupted time series models were devel-
oped with the following key covariates: valsartan initiation, initiation month, 
pre-initiation month, and post-initiation month. A similar time series model was used 
to forecast post-initiation medical costs for the same patients had they not initiated 
valsartan. The number of post-initiation months before the actual medical costs con-
verged with the forecasted medical costs was assessed as the time needed to reach the 
cost-offset point. RESULTS: Patients (N = 18,269) had mean age of 53 at the valsar-
tan initiation date, and 53% of them were female. The most common co-morbid con-
ditions were dyslipidemia (52%), diabetes (24%), hypertension with complications 
(17%), and ischemic heart disease (13%). The time series model estimated that 
medical costs were increasing about $10 per month (P < 0.01) prior to valsartan initi-
ation, and decreasing about $6 per month (P < 0.01) after the initiation. The actual 
medical cost reduction after valsartan initiation was statistically signiﬁcantly lower (P 
< 0.01) than the forecasted medical costs after the 2nd month. Similar trend was also 
observed in hypertension-related medical costs. CONCLUSIONS: Hypertension 
patients experienced increasing monthly medical cost prior to valsartan initiation. 
However, after initiation, there was a statistically signiﬁcant decrease in medical costs, 
which after only two months was signiﬁcantly lower than the forecasted costs of the 
same patients had they not initiated valsartan.
CV3
EFFECT OF BIVALIRUDIN ON ECONOMIC OUTCOMES OF STEMI 
PATIENTS IN AN OBSERVATIONAL DATASET
Kessler DP
Stanford University, Stanford, CA, USA
OBJECTIVES: Observational data provide an opportunity to assess drug efﬁcacy in 
the real world. However, because treatment decisions may be based on prognosis, 
estimates of treatment effects obtained from observational data may suffer from 
“confounding by indication.” To address this concern, we used a grouped-treatment 
approach to determine the impact of choice of anticoagulant on length of hospital 
stay (LOS) and cost in patients undergoing percutaneous coronary intervention (PCI). 
METHODS: We analyzed the Premier Perspective Database for all patients aged ≥18 
years admitted to Premier hospitals with a diagnosis of ST-elevated myocardial infarc-
tion (STEMI) and ≥1 procedure code for PCI between Q12004 and Q12008 (N = 
71,296). We constructed individual-level models of LOS and cost, similar to those in 
a conventional multivariate analysis, except that each individual’s actual treatment 
variables were replaced with grouped-treatment variables (the proportion of patients 
receiving each treatment at the hospital/year in which treatment occurred). We used 
linear regression to assess the impact of the likelihood of treatment with bivalirudin 
or heparin ± a glycoprotein IIb/IIIa inhibitor on LOS and cost (in 2008$), controlling 
for other treatments (including stent use, other drug use, CABG); patient demograph-
ics, diagnosis, insurance status, physician specialty; and hospital region, size, teaching 
status. We calculated conﬁdence intervals allowing for the clustering of errors at the 
hospital/year level. RESULTS: Bivalirudin treatment was associated with a reduction 
in LOS of 0.917 days (95% CI: −1.393, −0.441) and a reduction in cost of $4,554 
(95% CI: −7,936, −1,172) compared to heparin+GPI. CONCLUSIONS: Increasing 
the proportion of a hospital’s patients treated with bivalirudin was associated with a 
signiﬁcant reduction in LOS and cost, compared to heparin+GPI. The estimated effects 
of bivalirudin from a grouped-treatment model were signiﬁcantly larger than those 
from a conventional individual-level analysis, suggesting that confounding by indica-
tion may be important in this context.
